Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
Aptevo Therapeutics Inc. (APVO)
Last aptevo therapeutics inc. earnings: 8/9 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aptevotherapeutics.com/investor-overview
Company Research
Source: GlobeNewswire
New Preclinical Data Presented at the 2018 American Association for Cancer Research Annual Meeting Show Potent T-Cell Directed Tumor Killing with Reduced Cytokine Production Compared to a Competitor Bispecific Construct SEATTLE, April 16, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data for APVO436, a bispecific antibody candidate targeting CD123 and CD3, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The preclinical data demonstrate potent T-cell cytotoxicity of tumors expressing CD123 with limited cytokine release and suggest that APVO436 has the potential for increased clinical benefit and a favorable safety profile. Cytokine release syndrome (CRS) is a significant concern with T-cell activating therapies and has been associated with severe complications in clinical trials. Aptevo has previously p
Show less
Read more
Impact Snapshot
Event Time:
APVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APVO alerts
High impacting Aptevo Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
APVO
News
- Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Aptevo Therapeutics Announces Closing of $4.6 Million Public OfferingAccesswire
- Aptevo Therapeutics Provides Pipeline Update [Yahoo! Finance]Yahoo! Finance
APVO
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- APVO's page on the SEC website